ReviewNeuroscience letters2019
Human iPSC application in Alzheimer's disease and Tau-related neurodegenerative diseases.
Review in Neuroscience letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Human induced pluripotent stem cell models for Alzheimer's disease research: a bibliometric analysis.Frontiers in human neuroscience · 2025Pooled it
- Pooled it
- Autosomal allelic inactivation at loci with variable replication timing and dosage sensitivity.eLife · 2026Article
- The role for artificial intelligence in identifying combination therapies for Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2025Review
- Research on Alzheimer's Disease (AD) Involving the Use ofCentral nervous system agents in medicinal chemistry · 2025Review
- Primary cortical cell tri-culture to study effects of amyloid-β on microglia function and neuroinflammatory response.Journal of Alzheimer's disease : JAD · 2024Article
- Unlocking the therapeutic potential: odyssey of induced pluripotent stem cells in precision cell therapies.International journal of surgery (London, England) · 2024Review
- Transcription Factor-Mediated Generation of Dopaminergic Neurons from Human iPSCs-A Comparison of Methods.Cells · 2024Article
- Studying Microtubule Dynamics in Human Neurons: Two-Dimensional Microtubule Tracing and Kymographs in iPSC- and SH-SY5Y-Derived Neurons for Tau Research.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Low glucose induced Alzheimer's disease-like biochemical changes in human induced pluripotent stem cell-derived neurons is due to dysregulated O-GlcNAcylation.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Mutations in human DNA methyltransferase DNMT1 induce specific genome-wide epigenomic and transcriptomic changes in neurodevelopment.Human molecular genetics · 2023Article
- Alzheimer's Disease Treatment: The Search for a Breakthrough.Medicina (Kaunas, Lithuania) · 2023Review
- Altered O-GlcNAcylation and mitochondrial dysfunction, a molecular link between brain glucose dysregulation and sporadic Alzheimer's disease.Neural regeneration research · 2023Article
- Review
- Human iPSC-Derived Neural Models for Studying Alzheimer's Disease: from Neural Stem Cells to Cerebral Organoids.Stem cell reviews and reports · 2022Review
- Uncovering specificity of endogenous TAU aggregation in a human iPSC-neuron TAU seeding model.iScience · 2022Article
- Deconstructing Alzheimer's Disease: How to Bridge the Gap between Experimental Models and the Human Pathology?International journal of molecular sciences · 2021Review
- Review
- Genetic architecture of Alzheimer's disease.Neurobiology of disease · 2020Review
- Human-Induced Pluripotent Stem Cells and Herbal Small-Molecule Drugs for Treatment of Alzheimer's Disease.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Alzheimer's disease (AD) is a chronic neurodegenerative disorder characterized by β-amyloid (Aβ) plaques and neurofibrillary tangles with progressive cognitive decline. After years of research with failed clinical trials surrounding Aβ and tau using numerous in vitro and in vivo AD transgenic animals, human model is necessary to advance our understanding of AD and drug discovery. Induced pluripotent stem cells (iPSCs) offers a novel approach for the establishment of a human model that reflects human genetics and physiology to investigate mechanisms of AD and other forms of dementia, which potentially could lead to a drug discovery, followed by treatment for the disease. In this review, I discuss the advantages in using iPSC technology with various forms of modeling, the progress that has been made to date in patient-derived AD iPSC model and challenges posed by using this technology. Finally, I suggest the future directions of disease modeling and the potential of iPSC technology in AD and other neurodegenerative research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.